Compass, CARA, MNMD. As you said, no one has been spared.
And that’s exactly why the board made the decision not to raise capital for their NASDAQ listing. IHL shareholders interests are once again protected by a board that exercised prudent and disciplined management.
Does this reduce the potential upside of the clinical programs, including OSA? No, it doesn’t.
Industry news, page-521
-
- There are more pages in this discussion • 378 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)